Baldwin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.80 M
as on 08-12-2024
- Paid Up Capital ₹ 0.80 M
as on 08-12-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 4.00 M
as on 08-12-2024
- Satisfied Charges ₹ 1.10 M
as on 08-12-2024
- Revenue -38.56%
(FY 2020)
- Profit 46.23%
(FY 2020)
- Ebitda 79.72%
(FY 2020)
- Net Worth -91.36%
(FY 2020)
- Total Assets -5.26%
(FY 2020)
About Baldwin Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.80 M and a paid-up capital of Rs 0.80 M.
The company currently has active open charges totaling ₹4.00 M. The company has closed loans amounting to ₹1.10 M, as per Ministry of Corporate Affairs (MCA) records.
Preeti Gupta, Vipen Mahajan, and Simranjeet Singh serve as directors at the Company.
- CIN/LLPIN
U52100JK2015PTC004504
- Company No.
004504
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Sep 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Jammu
Industry
Company Details
- Location
Jammu, Jammu & Kashmir, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Baldwin Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Preeti Gupta  | Director | 22-Sep-2015 | Current |
| Vipen Mahajan | Director | 22-Sep-2015 | Current |
| Simranjeet Singh | Director | 22-Sep-2015 | Current |
Financial Performance of Baldwin Pharmaceuticals.
Baldwin Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 38.56% decrease. The company also saw a substantial improvement in profitability, with a 46.23% increase in profit. The company's net worth observed a substantial decline by a decrease of 91.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Baldwin Pharmaceuticals?
In 2019, Baldwin Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 May 2016 | ₹4.00 M | Open |
The Jammu And Kashmir Bank Limited Creation Date: 19 Jan 2016 | ₹1.10 M | Satisfied |
How Many Employees Work at Baldwin Pharmaceuticals?
Unlock and access historical data on people associated with Baldwin Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Baldwin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Baldwin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
